PMID- 16453260
OWN - NLM
STAT- MEDLINE
DCOM- 20060414
LR  - 20071115
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 193
IP  - 5
DP  - 2006 Mar 1
TI  - Human leukocyte antigen haplotypes in the genetic control of immune response to 
      measles-mumps-rubella vaccine.
PG  - 655-63
AB  - To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and 
      their genotypic combinations to immune status after measles-mumps-rubella (MMR) 
      vaccination, 346 children 12-18 years of age were studied. The class I 
      A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G 
      (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The 
      A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to 
      measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II 
      DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to 
      measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 
      haplotype was associated with high levels of IgG antibody to measles virus 
      (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas 
      DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to 
      both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was 
      associated with both mumps virus-specific humoral (P=.007) and cell-mediated 
      (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype 
      DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody 
      levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). 
      Better characterization of such HLA profiles could inform and improve the design 
      of novel epitope-rich vaccines and help to predict protective immune responses at 
      the individual and population level.
FAU - Ovsyannikova, Inna G
AU  - Ovsyannikova IG
AD  - Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, Minnesota 
      55905, USA.
FAU - Pankratz, V Shane
AU  - Pankratz VS
FAU - Vierkant, Robert A
AU  - Vierkant RA
FAU - Jacobson, Robert M
AU  - Jacobson RM
FAU - Poland, Gregory A
AU  - Poland GA
LA  - eng
GR  - AI 33144/AI/NIAID NIH HHS/United States
GR  - AI 48793/AI/NIAID NIH HHS/United States
GR  - MO1 RR00585/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060127
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antibodies, Viral)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (rubella antibodies)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Viral/*blood
MH  - Child
MH  - HLA Antigens/*genetics/*immunology
MH  - *Haplotypes
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunoglobulin G/blood
MH  - *Lymphocyte Activation
MH  - Lymphocytes/immunology
MH  - Measles virus/immunology
MH  - Measles-Mumps-Rubella Vaccine/*immunology
MH  - Mumps virus/immunology
MH  - Statistics as Topic
EDAT- 2006/02/03 09:00
MHDA- 2006/04/15 09:00
CRDT- 2006/02/03 09:00
PHST- 2005/06/24 00:00 [received]
PHST- 2005/09/22 00:00 [accepted]
PHST- 2006/02/03 09:00 [pubmed]
PHST- 2006/04/15 09:00 [medline]
PHST- 2006/02/03 09:00 [entrez]
AID - JID35192 [pii]
AID - 10.1086/500144 [doi]
PST - ppublish
SO  - J Infect Dis. 2006 Mar 1;193(5):655-63. doi: 10.1086/500144. Epub 2006 Jan 27.